About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The research group is focused on finding new molecular therapeutic targets and biomarkers based on knowledge of the biology of paediatric tumours, leukemias and hematologic diseases. The experience of the group in recent years has permitted the identification of new molecular targets that are very close to the clinical phase. In this stage, we have consolidated collaborations with the biotechnological industry in order to develop small molecules able to inhibit pro-oncogenic processes such as invasion or proliferation, with the aim of providing patients with innovative and more specific biological evidence-based therapies.
Another line of research is based on the study of liquid biopsy to develop a system based on NGS to monitor the probability of relapses.
Furthermore, we have implemented a personalized medicine program to guide the management of patients based on the molecular alterations of their tumours
IP: M Mar Mañu Pereira Collaborators: Reidel , Sara Isabel, Sara Isabel Reidel, Daiana Natali Lopez Funding agency: EUROPEAN COMMISSION Funding: 253750 Reference: IMPACT-AML_HE--MISS-CANCER2022 Duration: 01/04/2023 - 31/03/2028
IP: Lucas Moreno Martín-Retortillo Collaborators: Luís Gros Subias, Raquel Andreu Vilarroig, Andrea Vilaplana Blanes, Pablo Velasco Puyó, Laura Murillo Sanjuán, Maria Isabel Benitez Carabante, Aroa Soriano Fernández, Guillem Pons Barcons, Jose Miguel Lizcano De Vega, Maria Cristina Díaz de Heredia Rubio, Maria Luz Uría Oficialdegui, Maria Jose Pérez García, Miguel Segura Ginard, M Mar Mañu Pereira, Lorena Valero Arrese, Thaïs Murciano Carrillo, Constantino Sábado Álvarez, Anna Llort Sales, Raquel Hladun Alvaro, Carlota Aguilera Ordoñez, Adria Molero Valenzuela, Grup de Recerca Emergent (GRE) Childood Cancer & Blood disorders, Gabriela Guillén Burrieza, Laura Alonso Garcia, Idoia Bolinaga Ayala, Josep Roma Castanyer, Sergio Espinosa Gil, Elena Andretta, Claire Diot, Amira Idrizovic Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 60000 Reference: 2021 SGR 00638 Duration: 01/01/2022 - 30/06/2025
IP: Lucas Moreno Martín-Retortillo Collaborators: Implementación de la Oncología de Precisión en Pacientes Adolescentes y Adultos Jóvenes con Cáncer, María Paula Pérez Albert Funding agency: Instituto de Salud Carlos III Funding: 65000 Reference: CM22/00241 Duration: 01/01/2023 - 31/12/2024
IP: M Mar Mañu Pereira Collaborators: Reidel , Sara Isabel, Sara Isabel Reidel, Claire Diot Funding agency: EUROPEAN COMMISSION Funding: 435938 Reference: SYNTHEMA_HE-HLTH22_IND13 Duration: 01/12/2022 - 30/11/2026
The initiative will enable young people aged 12 to 18 to collaborate with campus researchers in the design, development and communication of scientific projects, placing patients and families at the centre of the research process.
The REACH5 study confirms that the efficacy and safety results observed in previous studies are maintained after three years of follow-up.
In-depth knowledge of tumours helps identify specific alterations and enables the provision of targeted therapies for each patient.
